Media

Efficacy and hazards of 425 nm oral cavity light dosing to inactivate SARS-CoV-2

Economic and clinical impact of a novel, light based, at-home antiviral treatment on mild-to-moderate COVID-19

A randomized, controlled, feasibility study of RD-X19 in subjects with mild-to-moderate COVID-19 in the outpatient setting

Visible blue light inhibits infection and replication of SARS-CoV-2 at doses that are well-tolerated by human respiratory tissue

Visible blue light inactivates SARS-CoV-2 variants and inhibits Delta replication in differentiated human airway epithelia

Exploring light as a pan-variant therapeutic for COVID-19; Biosafety Considerations of the Biological Light Unit

A Phase II, Randomized, Sham-Controlled Dose- Finding Study of the RD-X19 Treatment Device in Individuals with Mild-to-Moderate COVID-19

The Impact of Blue-Light Emitting Device on the Loss of Productivity From COVID-19 in North Carolina

EmitBio to Present Research on Novel Light-Based Antiviral Therapy at the World Congress on Infectious Diseases (October 23-25, 2023)

COVID-19 treatment at home could come from Durham firm’s blue light tech

Researchers Suggest That Visible Blue Light Is a Safe and Variant-Agnostic Therapy against SARS-CoV-2

Emitbio, BioTech Developing a light Treatment for Corona

Study: EmitBio’s Blue Light Biotech can Eliminate 99.99% of Omicron in Lab Setting

Local Firm to Host Trials for Home COVID Treatment

InnovationRX: The Boomers Are OK; Plus, Covid Mu Variant

This Company Wants To Treat Mild Cases Of Covid With LED Lights

Durham company says its light treatment kills COVID-19 and variants in the throat

Emitbio seeks EUA for light-based COVID-19 treatment to be used at home

NC company develops light-based device to kill COVID-19 in the body; now, they’re seeking emergency authorization

Durham-Based Startup Could Have New COVID-19 Treatment

EmitBio’s technology shows evidence to inactivate multiple coronaviruses

EmitBio Seeks to Provide Light at the End of the COVID-19 Treatment Tunnel

Durham company producing light technology that treats COVID-19

EmitBio Unveils Positive Early Results for Handheld COVID-19 Therapeutic

EmitBio Presenting at the World Congress on Infectious Diseases

Projects Annual Savings of Over $4 Billion

Treatment Effective against Omicron in Vitro

Covering Light to Treat COVID-19 and Other Diseases

Yield 99.99% Reduction of Delta in Human Tissue

Broadly Effective against Coronavirus Variants

Emitbio Reduces Viral Load in Clinical Trial

Emitbio Demonstrates New Treatment Is Effective against Multiple Types of Coronavirus

Emitbio Announces Positive Clinical Results Supporting a Novel Therapeutic for COVID-19